Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 13/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205899 | 0.94 | EPHX1 (0.40) | EPHX1ACHECYP1A2CA12CA1 | |
| SCHEMBL27684736 | 0.92 | EPHX1 (0.43) | EPHX1ACHECA12CA1CA2 | |
| SCHEMBL28056747 | 0.92 | EPHX1 (0.43) | EPHX1ACHECA12CA1CA2 | |
| SCHEMBL2641404 | 0.91 | EPHX1 (0.33) | EPHX1ACHECYP1A2 | |
| Hydrochloric Acid SCHEMBL27247810 | 0.91 | EPHX1 (0.42) | EPHX1ACHECA12CA1CA2 | |
| SCHEMBL12502048 | 0.88 | HDAC6 (0.42) | ACHECYP1A2CA12CA1CA2 | |
| SCHEMBL2703359 | 0.88 | ALDH1A1 (0.33) | EPHX1ACHE | |
| SCHEMBL28659907 | 0.86 | PAOX (0.45) | ACHECYP1A2CA12CA1CA2 | |
| Methane SCHEMBL27985713 | 0.86 | ALDH1A1 (0.33) | EPHX1ACHE | |
| Hydrochloric Acid SCHEMBL27716907 | 0.86 | ALDH1A1 (0.33) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024210572-A1 | NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF | 주식회사 펠레메드 | 2024-10-10 | — | — | WO | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112074507-B | Compounds as Antibiotics | 山东亨利医药科技有限责任公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023151559-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND ANTI-TUMOR USE THEREOF | 和径医药科技（上海）有限公司 | 2023-08-17 | — | — | WO | disclosed |
| WO-2023098730-A1 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | 正大天晴药业集团股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2020132582-A1 | STING AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| CN-110520413-A | Big ring broad-spectrum antibiotic | RQX PHARMACEUTICALS INC | 2019-11-29 | — | — | CN | disclosed |
| CN-110520409-A | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX INC | 2019-11-29 | — | — | CN | disclosed |
| CN-106164072-B | Monocyclic lactam organic compounds for the treatment of bacterial infections | 诺华股份有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-110114344-A | New pyrimidine compound and preparation method thereof, and contain pharmaceutical composition of the compound as prevention or treating cancer and the active constituent of diseases associated with inflammation | 韩国化学研究院 | 2019-08-09 | — | — | CN | disclosed |
| CN-101855221-A | Pyridazinone derivatives as PARP inhibitors | ANGELETTI P IST RICHERCHE BIO | 2010-10-06 | — | — | CN | disclosed |
| CN-1993361-B | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP | 2010-05-26 | — | — | CN | disclosed |
| CN-101687867-A | imidazoquinolines with immuno-modulating properties | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| CN-101421250-A | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them | EXELIXIS INC (US) | 2009-04-29 | — | — | CN | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| CN-101094837-A | Novel beta agonists, method for producing the same and their use as drugs | BOEHRINGER INGELHEIM INT (DE) | 2007-12-26 | — | — | CN | disclosed |
| CN-1993361-A | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
| CN-1826116-A | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2006-08-30 | — | — | CN | disclosed |
| CN-1809563-A | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | CHIRON CORP (US) | 2006-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | EPHX1 985/4885ACHE 1041/4885CYP1A2 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.